{
  "id": 19783817,
  "title": "Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028",
  "url": "https://urgent.news/2026/11/13/prediction-10-000-invested-in-viking-therapeutics-before-its-oral",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T09:15:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/13/predict-10k-invested-viking-therapeutics-obesity/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Viking Therapeutics (VKTX) currently holds four phase 3 trials for its key drug, VK2735, which could potentially be worth a significant amount by 2028. The two subcutaneous (injectable) trials are already underway, with data expected in the second half of 2027. Meanwhile, the two oral phase 3 trials have just begun and are projected to provide data in 2028. The oral trials have the potential to expand the drug's addressable market by offering a dual-formulation strategy. Viking Therapeutics' success will depend on the efficacy and tolerability of VK2735 compared to its competitors. Based on current data, if VK2735 manages to secure 10% of the projected sales of a similar drug, its peak sales could amount to approximately $7 billion. However, due to the uncertainties surrounding the clinical trials, it is estimated that peak sales could be around $3.5 billion. With a conservative assumption of a 50% probability of success, Viking Therapeutics could have a market cap of $10.5 billion to $17.5 billion. At its current trading price, a $10,000 investment could potentially be worth up to $47,800 by 2028. The Motley Fool's Stock Advisor services may provide further insights into potential investment opportunities.",
  "summary": "Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.",
  "key_points": [
    "Viking Therapeutics (VKTX) has four phase 3 trials for VK2735 drug.",
    "Two oral phase 3 trials began, projected to provide data in 2028.",
    "$10,000 investment could be worth up to $47,800 by 2028."
  ],
  "editors_take": "A dual-formulation strategy for VK2735 positions Viking Therapeutics to capture a larger market share if the upcoming oral and injectable phase 3 trials prove successful against existing competitors.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}